Skip to main content
SpringerLink
Log in

Pregnancy outcomes in women with type 1 diabetes using insulin degludec: response to Kamran et al

  • Letter to the Editor
  • Published:
Acta Diabetologica Aims and scope Submit manuscript

The Original Article was published on 25 October 2022

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Ringholm L, Do NC, Damm P, Mathiesen ER (2022) Pregnancy outcomes in women with type 1 diabetes using insulin degludec. Acta Diabetol 59:721–727

    Article  CAS  Google Scholar 

  2. Davies MJ, Gross JL, Ono Y et al (2014) Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial. Diabetes Obes Metab 16:922–930

    Article  CAS  Google Scholar 

  3. Lane W, Bailey TS, Gerety G et al (2017) Effect of Insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 1 diabetes: the SWITCH 1 randomized clinical trial. JAMA 318:33–44

    Article  CAS  Google Scholar 

  4. Keller MF, Vestgaard M, Damm P, Mathiesen ER, Ringholm L (2019) Treatment with the long-acting insulin analog degludec during pregnancy in women with type 1 diabetes: an observational study of 22 cases. Diabetes Res Clin Pract 152:58–64

    Article  CAS  Google Scholar 

  5. https://clinicaltrials.gov/ct2/show/NCT03377699

Download references

Acknowledgements

L. Ringholm has received a research grant from Novo Nordisk (Grant number: U1111-1209-6358) for an investigator-sponsored study.

Funding

None.

Author information

Authors and Affiliations

  1. Center for Pregnant Women with Diabetes, Rigshospitalet, University Hospital of Copenhagen, Blegdamsvej 9, 2100, Copenhagen, Denmark

    Lene Ringholm, Nicoline Callesen Do, Peter Damm & Elisabeth Reinhardt Mathiesen

  2. Department of Endocrinology and Metabolism, Rigshospitalet, University Hospital of Copenhagen, Blegdamsvej 9, 2100, Copenhagen, Denmark

    Lene Ringholm, Nicoline Callesen Do & Elisabeth Reinhardt Mathiesen

  3. Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3b, 2200, Copenhagen, Denmark

    Nicoline Callesen Do, Peter Damm & Elisabeth Reinhardt Mathiesen

  4. Department of Obstetrics, Rigshospitalet, University Hospital of Copenhagen, Blegdamsvej 9, 2100, Copenhagen, Denmark

    Peter Damm

Authors
  1. Lene Ringholm
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicoline Callesen Do
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Damm
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elisabeth Reinhardt Mathiesen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lene Ringholm.

Ethics declarations

Conflict of interest

ERM has received fees for giving talks for Novo Nordisk A/S. ERM, PD and LR are participating in multicenter and multinational clinical studies on the use of insulin in pregnant women with pre-existing diabetes in collaboration with Novo Nordisk; no personal honorarium is involved. NCD is funded by Novo Nordisk Foundation.

Ethical approval

The study [1] was in accordance with the Helsinki declaration. In addition, the study was approved by The National Committee on Health Research Ethics (H-15019186 and H-15009413) and The Danish Data Protection Agency (2012-58-0004, RH-2015-289, I-Suite: 04305).

Informed consent

All participants gave written informed consent before the data collection for the study [1].

Additional information

Managed By Antonio Secchi.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article belongs to the topical collection Eye Complications of Diabetes, managed by Giuseppe Querques.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ringholm, L., Do, N.C., Damm, P. et al. Pregnancy outcomes in women with type 1 diabetes using insulin degludec: response to Kamran et al. Acta Diabetol 60, 141–142 (2023). https://doi.org/10.1007/s00592-022-01996-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00592-022-01996-8

Search

Navigation